Remarkably, treatment with ITGB4-DC vaccine or ITGB4-BiAb TDLN T cells did not improve 4T1-ITGB4KO tumor growth, strongly suggesting that both of our ITGB4-targeted immunological strategies were ITGB4 specific. This evidence concerns the gene ITGB4 and neoplasm.